Opendata, web and dolomites

TNT-TUMORS SIGNED

Therapeutic approaches to enhance innate immunity against Tumors

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TNT-TUMORS project word cloud

Explore the words cloud of the TNT-TUMORS project. It provides you a very rough idea of what is the project "TNT-TUMORS" about.

activated    strategies    instructed    macrophages    completely    independent    tams    utilize    recognition    genetic    human    look    effect    validated    types    killing    capacity    cooperation    cancers    therapies    mimicking    power    translation    direct    start    checkpoint    endowing    immunemodulatory    cells    therapeutic    tumors    models    molecular    mouse    tam    tumorigenesis    immunetherapy    specificity    possibility    clinicians    reevaluate    pdcs    immune    fast    anti    shows    egfr    cancer    never    ensures    inhibitors    adaptive    patients    interaction    tumor    tumorigenic    immunemodulation    first    samples    rnai    plan    recent    poorly    significance    phenotype    restrained    fight    expressing    clinical    vivo    close    screens    molecularly    predictive    occurs    interesting    subset    treatment    capacities    cell    standard    innate    mechanism    vitro    drugs    dendritic    modulation    platform    mechanisms    dissect    metastasis    harness    plasmacytoid    inducible    attack   

Project "TNT-TUMORS" data sheet

The following table provides information about the project.

Coordinator
MEDIZINISCHE UNIVERSITAET WIEN 

Organization address
address: SPITALGASSE 23
city: WIEN
postcode: 1090
website: www.meduniwien.ac.at

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Austria [AT]
 Project website https://krebsforschung.meduniwien.ac.at/forschung-research/research-focuses/cellular-and-molecular-tumor-biology/maria-sibilia/
 Total cost 2˙499˙646 €
 EC max contribution 2˙499˙646 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2015-AdG
 Funding Scheme ERC-ADG
 Starting year 2016
 Duration (year-month-day) from 2016-09-01   to  2021-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MEDIZINISCHE UNIVERSITAET WIEN AT (WIEN) coordinator 2˙499˙646.00

Map

 Project objective

Recent advances using immune checkpoint inhibitors demonstrate the great potential of immunemodulation in cancer and metastasis treatment. However, the effective treatment of only a subset of patients shows that this is only the start to utilize the power of the immune system to fight cancer. An interesting approach is to harness innate immune cells, such as plasmacytoid dendritic cells (pDCs) and tumor-associated macrophages (TAM) to attack tumors and to enhance the effect of standard anti-cancer therapies. Recently, using mouse models we identified two independent mechanisms by which modulation of these two cell types restrained tumor growth. First, the direct killing of tumor cells by pDCs that occurs independent of the adaptive immune system. Second, we identified a tumor-promoting role of EGFR-expressing (EGFR) TAMs during tumorigenesis. This enables us to look at the role of EGFR in tumorigenesis in a completely new way and we plan to exploit this novel finding to reevaluate the mechanism by which anti-EGFR drugs are effective in tumors. The mechanisms endowing pDCs with tumor-killing capacities and determining the specificity of tumor cell recognition by activated pDCs are poorly understood. Furthermore, the interaction of pDCs with macrophages has never been investigated in tumors. Here I propose to define the molecular mechanisms by which pDCs and TAMs can be instructed to adopt an anti-tumorigenic phenotype. Inducible and cell-specific genetic mouse models mimicking human cancers will allow to molecularly dissect the immunemodulatory capacity of pDCs and TAMs. State-of-the-art large scale in vitro and in vivo RNAi screens will provide a platform to identify novel molecular pathways and open the possibility for testing new strategies in cancer immunetherapy. The clinical significance of our findings will be validated in human cancer samples in close cooperation with clinicians, which ensures a fast predictive and therapeutic translation of our results.

 Publications

year authors and title journal last update
List of publications.
2017 Sriram Srivatsa, Mariel C. Paul, Claudia Cardone, Martin Holcmann, Nicole Amberg, Paulina Pathria, Michaela A. Diamanti, Markus Linder, Gerald Timelthaler, Hans P. Dienes, Lukas Kenner, Fritz Wrba, Gerald W. Prager, Stefan Rose-John, Robert Eferl, Giuseppina Liguori, Gerardo Botti, Erika Martinelli, Florian R. Greten, Fortunato Ciardiello, Maria Sibilia
EGFR in Tumor-Associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients
published pages: 178-190.e10, ISSN: 0016-5085, DOI: 10.1053/j.gastro.2017.03.053
Gastroenterology 153/1 2020-04-08
2018 Markus Linder, Elisabeth Glitzner, Sriram Srivatsa, Latifa Bakiri, Kazuhiko Matsuoka, Parastoo Shahrouzi, Monika Dumanic, Philipp Novoszel, Thomas Mohr, Oliver Langer, Thomas Wanek, Markus Mitterhauser, Erwin F Wagner, Maria Sibilia
EGFR is required for FOS‐dependent bone tumor development via RSK2/CREB signaling
published pages: e9408, ISSN: 1757-4676, DOI: 10.15252/emmm.201809408
EMBO Molecular Medicine 10/11 2020-04-08
2018 Stefanie Schmidt, Neele Schumacher, Jeanette Schwarz, Simone Tangermann, Lukas Kenner, Michaela Schlederer, Maria Sibilia, Markus Linder, Annelore Altendorf-Hofmann, Thomas Knösel, Elisabeth S. Gruber, Georg Oberhuber, Julia Bolik, Ateequr Rehman, Anupam Sinha, Juliane Lokau, Philipp Arnold, Anne-Sophie Cabron, Friederike Zunke, Christoph Becker-Pauly, Adele Preaudet, Paul Nguyen, Jennifer Huynh, Shoukat Afshar-Sterle, Ashwini L. Chand, Jürgen Westermann, Peter J. Dempsey, Christoph Garbers, Dirk Schmidt-Arras, Philip Rosenstiel, Tracy Putoczki, Matthias Ernst, Stefan Rose-John
ADAM17 is required for EGF-R–induced intestinal tumors via IL-6 trans-signaling
published pages: 1205-1225, ISSN: 0022-1007, DOI: 10.1084/jem.20171696
The Journal of Experimental Medicine 215/4 2020-04-08
2018 Markus Linder, Manfred Hecking, Elisabeth Glitzner, Karin Zwerina, Martin Holcmann, Latifa Bakiri, Maria Grazia Ruocco, Jan Tuckermann, Georg Schett, Erwin F. Wagner, Maria Sibilia
EGFR controls bone development by negatively regulating mTOR-signaling during osteoblast differentiation
published pages: 1094-1106, ISSN: 1350-9047, DOI: 10.1038/s41418-017-0054-7
Cell Death & Differentiation 25/6 2020-04-08

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TNT-TUMORS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TNT-TUMORS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

DISINTEGRATION (2019)

The Mass Politics of Disintegration

Read More  

VictPart (2019)

Righting Victim Participation in Transitional Justice

Read More  

DimorphicCircuits (2019)

Elucidating the development of sexually-dimorphic circuits: from molecular mechanisms to synapses and behavior

Read More